Web notes  

August 2018

SANOFI Innovation Awards Program

Internal deadline: September 15, 2018

Johns Hopkins University School of Medicine and sixteen other major peer institutions (Brigham and Women’s Hospital, Columbia University, Massachusetts General Hospital, Boston Children’s Hospital, University of Pennsylvania, Weill Cornell Medical Center, Stanford University, UCLA, UCSF, New York University, Northeastern University, Children’s Hospital of Philadelphia, Dana Farber Cancer Center, Sinai Health (Toronto), Sunnybrook Health (Toronto) and University Health Network (Toronto)) have entered into an agreement with SANOFI for their fourth Innovations Awards Program. If proposed projects are selected they will receive a one-year award for $125,000 including indirect costs, which may be renewable for an additional year and/or successful Innovation Awards projects may receive additional ongoing sponsored awards beyond the Innovation Program. The Innovation Awards Agreement includes pre-negotiated terms of the Innovation Awards and additional follow-on Sponsored Awards with publication rights for the investigators and an IP option for SANOFI.

To be eligible for consideration, projects will go through a two stage review; 1) first submit to Karen Falter (kjustice@jhmi.edu) a brief non-confidential pre-proposal by September 15, 2018, and 2) SANOFI will select from the pre-proposals those projects that will be asked to prepare a more detailed confidential proposal by October 15th, under guidelines issued at that time. The requested detailed proposals will be due on November 5th and will be reviewed by a Joint Scientific Committee that includes a scientist from each of the participating institutions as well as from SANOFI. Selected awards are expected to be announced early December.

Please submit innovative translational research ideas that align with SANOFI's stated areas of interest in the RFP document. Unfunded previous internal and external proposals and new proposal ideas can be used. Funding Awards are only available for research conducted by researchers at this institution that does not involve a third-party collaborator. A third party-collaborator is considered (i) any researcher employed by an institution or entity that is not an institution/entity participating in the iAwards program, (ii) a funding source involving any organization or entity other than a state or federal government agency, or (iii) a third party for which the confidential information, materials, or methods or models described in the proposal involve third-party rights that may restrict the Parties’ intellectual property rights as set forth in the Funding Award Agreement template.

If you have any questions, please contact Karen Falter (kjustice@jhmi.edu).

NIH Director's Early Independence Award (DP5 - Clinical Trial Optional)

Application deadline: August 16, 2018

The NIH Director's Early Independence Award supports exceptional investigators who wish to pursue independent research essentially directly after completion of their terminal doctoral/research degree or end of post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. Applications are welcome from individuals of diverse backgrounds and perspectives and in any topic of relevance to the broad mission of NIH. The NIH Director's Early Independence Award is part of the High-Risk, High-Reward Research program funded through the NIH Common Fund. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address major problems that are especially daunting or to seize new opportunities that offer the potential for rapid progress. Johns Hopkins may nominate up to 2 investigators for this $1,250,000 (direct costs only) award.

Eligibility & Requirements:

  • The receipt date of the terminal doctoral degree or end of post-graduate clinical training of the PD/PI must be between June 1, 2017 and September 30, 2019.
  • At the time of application, the PD/PI must not have served as a post-doctoral fellow following a previous (not the most recent) doctoral degree for more than twelve months.
  • Only single PD/PI applications are allowed.
  • Individuals must commit at least 9.6 person-months each year during the first two years of the project period to research supported by the Early Independence Award. In the final three years of the project period, awardees may reduce effort toward the Early Independence Award project, but the total effort towards independent research in general must remain at least 9.6 person-months each year.
  • Individuals are eligible only if they, at the time of application submission, do not have research independence.
  • Eligible individuals must have all the following characteristics:
    • The PD/PI's current research agenda is set through concurrence with mentors.
    • The PD/PI's research is funded primarily through support to other investigators (mentored fellowships such as NIH F31 or F32 Fellowships or NSF Graduate Research Fellowships do not preclude eligibility).
    • The PD/PI does not have any space assigned directly by the institution for the conduct of his/her research.
    • The PD/PI, according to institutional policy, cannot apply for an NIH R01 grant without special waiver or exemption from the institution.

Internal Nomination Process:
Interested applicants should submit the following documents:

  1. JHU Limited Submission Cover Sheet
  2. Proposal (maximum of two pages of text only, single spaced: 12-pt font and one-inch margins) (Note: figures, tables, and other reference material may be included in addition to the 2 pg. text limit)
  3. Curriculum Vitae of investigator, including current external research support and publications
  4. Budget (two pages maximum)

For more information visit https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-18-010.html. Questions? Comments? Email the Research Development Team at resapp@jhu.edu.

Michael J. Fox Foundation (MJFF) Challenge

No application deadline

The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.

The ability to image alpha-synuclein deposition in the brain would be a game-changing achievement for the Parkinson's disease (PD) field. The accumulation of aggregated alpha-synuclein is a pathological hallmark of PD and a priority target for drug development given its hypothesized contribution to neurodegeneration. In vivo imaging of alpha-synuclein pathology could be useful as a biomarker of the presence of disease and disease progression and as a pharmacodynamic tool for drug development. With this prize, the Foundation seeks to attract research teams and accelerate momentum to speed the development of such a tracer.

Contestants: Anyone is eligible for the prize who agrees to all contest rules. Contestants may be MJFF funded or not and can be from either academia or industry.

Contest rules:

  1. Contestants must apply for the prize with pre-clinical and clinical data supporting the broad use of their alpha-synuclein radiotracer. Judges may ask for additional data, including but not limited to raw imaging data.
  2. NOTE: All contestants must agree to make the winning radiotracer available for use by The Michael J. Fox Foundation and MJFF awardees through a nonexclusive license or other MJFF-approved mechanism.

Criteria for winning: The winning contestant must demonstrate that the radiotracer binds with relatively high selectivity to alpha-synuclein according to pre-specified criteria and must demonstrate proof-of-concept in human subjects, including people with Parkinson's disease and/or another synucleinopathy. See below for more details on submission requirements.

Timeline: There is no deadline for submissions. The $2 million award will be issued to the first contestant who submits compelling evidence of a viable selective tracer and agrees to its widespread use. If no award is given by mid-2018, The Michael J. Fox Foundation will evaluate the state of the field and utility of such a prize.

Return to top of Funding Opportunities

August 2018 articles:
Change in JHM IRB Review Fees for Commercially-Funded Studies
Data and Safety Monitoring Board Training Manual Now Available
Good Clinical Practice (GCP) Fundamentals: Understanding and Applying GCP to Human Subject Research
Fee Schedule Adjustment for Hospital Services Charged to Clinical Trial Budgets
Change in Federalwide Assurance [FWA] Numbers
Changes to NIH-funded Human Subjects Research
Free Resources for Longitudinal Clinical Research Studies
NIH requirement for Single IRB (sIRB)
JHM IRB Reliance Requests
Sharing Partnership for Innovative Research in Translation
Johns Hopkins Institute for Clinical and Translational Research
Johns Hopkins Research Network
Visit Animal Care and Use Committee Website
Current Classes
"Interinstitutional Assurance" Agreement
Health, Safety, and Environment (HSE) presents: Safety in Research Updates
SANOFI Innovation Awards Program
NIH Director's Early Independence Award (DP5 - Clinical Trial Optional)
Michael J. Fox Foundation (MJFF) Challenge
Why Project Outcomes Matter in your Interim and Final Research Performance Progress Report (RPPR)
NIH Matchmaker, A Tool For Finding Similar NIH Projects
NIH Video Tutorials on How to Apply for Grants
NIH Policy: Foreign Components Added to a Grant to a Domestic or Foreign Organization

This Month's Departmental Listings

Upcoming Deadlines for September and October

August Events at the Genetic Resources Core Facility


JHM AppointmentsEmployment @ JHM | Finding a Doctor | Disclaimer | Maps & Directions | Contact JHM 


                                                                                                                                                           The Web Center